Curve Therapeutics’ CSO Ali Tavassoli has published an article in the Journal of the American Chemical Society (JACS) which highlights the potential of HIF inhibition as a therapeutic approach for cancers.

The paper is titled ‘Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and 2 That Disrupt Hypoxia-Related Signalling in Cancer Cells’.  

Tavassoli co-authored the article and leads the academic group at the University of Southampton where the work was undertaken. He said: “It is well recognised that HIF plays a key role in the survival and growth of solid tumours. The compounds we report in this paper inhibit the protein-protein interaction of the two subunits that form the HIF transcription factor. We show that these compounds prevent the hypoxia-induced activity of this transcription factor, stopping hypoxia-response in cell-based assays. This paper underlines the promising therapeutic potential of dual HIF inhibition as an approach for the treatment of a variety of cancers.” 

Curve is developing a non-peptidic, small-molecule dual inhibitor of HIF-1 and HIF-2 with first-in-class potential. The microcycles discovered by Professor Tavassoli were identified using his SICLOPPS screening platform and show good cellular activity.  

This is reportedly the first finding of a dual HIF-1 and HIF-2 inhibitor which functions by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β.